Benitec Biopharma announced this week that a challenge to a key UK patent has been withdrawn, and that the amended claims in the patent have been accepted by the United Kingdom Intellectual Property Office.
According to the company, the patent — GB 2353282 — had been challenged in 2010 by a UK-based law firm on behalf of an unknown client. Benitec said it responded to all the issues raised in the challenge, deciding to “slightly amend” the IP to “provide greater clarity, in particular that the claims were to double-stranded constructs.”
The patent claims the use of recombinant DNA technology to post-transcriptionally modify or modulate the expression of a target gene in a cell, tissue, organ, or whole organism, according to its abstract.
Objections raised to certain of the amended claims were later dropped, Benitec said.